MEDVi grew fast on aggressive advertising and a low advertised entry price, and if you've searched for compounded GLP-1s in 2026 you've almost certainly seen it. Pallas Health is a smaller, GLP-1-focused telehealth platform with a different structure: one flat, all-in price and asynchronous care. Both advertise a lower first month for compounded semaglutide, and Pallas charges nothing until a clinician prescribes — so this comparison focuses on what the numbers become after month one, and on the terms that matter when you want to change course.
Pricing on both sides changes often — MEDVi's intro price in particular rotates with sales — so the figures here reflect each platform's published pricing as of August 2026. Confirm current numbers on both sites before signing up.
The three differences that matter most
- The renewal price, not the intro price. MEDVi's compounded semaglutide program starts at $149 for the first month (a running sale; it has also been advertised at $179), and MEDVi's own FAQ states refills are locked in at $299/month after that. Pallas's compounded semaglutide injection is $139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime. Pallas states the renewal in the same sentence as the first month, and nothing is charged until a clinician prescribes — the number worth comparing is what you'll pay in month four.
- The brand-name track. Through MEDVi, brand-name Wegovy® and Zepbound® require a $99/month membership plus the medication cost. Pallas has no membership on any tier: brand-name medications are cash-pay at their listed price, and compounded plans are one all-in number covering the provider, dose adjustments, messaging, and shipping.
- The exit terms. Pallas: cancel anytime, self-serve in the portal, and nothing charged unless a clinician prescribes. MEDVi's published policy requires cancellation at least 72 hours before your next billing date, states no refund is issued for the month in which you cancel, and refunds multi-month prepays only for months where no medication shipped. Neither is hidden — read both before committing anywhere.
About compounded medications
Compounded medications are prepared on a per-patient basis by US-licensed compounding pharmacies, regulated under federal law (FDCA §503A) and by state boards of pharmacy. A licensed clinician decides whether a compounded preparation — for example, a dose level or a formulation a brand-name product doesn't offer — is appropriate for you.
Pallas offers both FDA-approved and compounded medications. Compounded medications are not FDA-approved and are not generic versions of brand-name drugs. Eligibility and treatment are determined by a US-licensed clinician; results vary. Private pay only (no insurance). Operated by Brentmoor, Inc.
Quick comparison
| Pallas Health | MEDVi | |
|---|---|---|
| Compounded semaglutide injection | Yes — one all-in plan price | Yes — $149 first month (sale pricing), then $299/mo refills per their FAQ |
| Compounded oral forms | Semaglutide daily tablet, one all-in plan price | Dissolvable tablets from $249 |
| FDA-approved brand (Wegovy®, Zepbound®) | Yes, cash-pay — no membership | Yes — $99/mo membership + medication cost |
| Membership fee | None on any tier | None on compounded; $99/mo on the brand track |
| Price after the intro month | Stated up front, flat at every dose | $299/mo refills (semaglutide injections, per their FAQ) |
| If a clinician doesn't prescribe | Nothing charged | Refund on medical disqualification per their policy |
| Cancellation | Anytime, self-serve in portal | 72-hour notice before billing; no refund for the month of cancellation |
| Care team | Clinicians licensed in your state via the Pallas platform | Affiliated professional corporations via a third-party clinical network |
| Companion app | Free on iOS and Android, no subscription | Not offered |
| Insurance | Cash-pay (no insurance routing today) | Cash-pay |
| Year founded | 2026 | 2024 |
What MEDVi does well
A low entry price with free shipping. MEDVi's sale-priced first month for compounded semaglutide injections is among the lowest advertised entry points anywhere, shipping is free and fast, and there's no membership fee on the compounded track. If the first-month number is your only criterion, MEDVi's ads are telling the truth about it.
Oral options. MEDVi offers compounded dissolvable GLP-1 tablets (from $249) for patients who prefer to avoid injections, when a clinician judges an oral form appropriate. Pallas offers a compounded semaglutide daily tablet ($259/mo average on the 12-week plan) and, on the brand-name side, the FDA-approved Wegovy® pill and Foundayo™ (each $299 for the first month, then $499 every 4 weeks, cash-pay).
Scale. MEDVi reports serving hundreds of thousands of patients and carries a large volume of consumer reviews. It's a substantial operation with both compounded and brand-name tracks.
What Pallas does differently
The month-four math. Pallas prints the renewal in the same sentence as the first month, so month four is never a surprise: $139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime. That renewal is meaningfully below a $299/month refill rate, the price is flat at every dose, and there's no membership on any tier — including brand-name. Compounded tirzepatide injection is $179 first month, then $299 every 4 weeks, charged once a clinician prescribes. Cancel anytime. Everything — provider care, check-ins, dose adjustments, unlimited messaging, shipping — is inside the one number. Both plans, compounded semaglutide and compounded tirzepatide, are weekly injections with clinician care included.
Patient-friendly terms. Nothing is charged until a clinician prescribes. Cancel anytime, yourself, in the portal — no notice window, no charge for the month you cancel in, nothing to email.
Asynchronous care with a real portal relationship. In most states there's no video visit to schedule: complete the intake online, a clinician licensed in your state reviews it, and everything after that runs through portal messaging — side effects, dose questions, refills — with replies typically within a business day. Orders, refills, plan switches, and billing are all self-serve.
Both tiers, with compounding as personalization. Pallas dispenses FDA-approved Wegovy®, Ozempic®, Zepbound®, and Mounjaro®, and — when a clinician decides a brand isn't the right fit — compounded semaglutide or tirzepatide weekly injections. A clinician reaches for compounded as personalization a fixed-dose pen can't provide, not as a knockoff of the brand.
A free companion app. The Pallas companion app (Protein & GLP-1 Tracker, iOS and Android) tracks protein, steps, weight trend, and dose reminders — free, no subscription.
How to compare these two
Line the offers up on four questions, using each platform's own published terms:
- What's the renewal price? Compare month four, not month one. MEDVi's own FAQ states $299/month refills for semaglutide injections; Pallas states the plan amount, its interval, and that it renews until you cancel in the same sentence on every surface.
- Is there a membership? On brand-name medications, MEDVi adds $99/month; Pallas adds nothing.
- What happens if you stop? Read both cancellation policies side by side — notice windows, refund treatment for the current month, and multi-month prepay terms differ materially.
- What can you verify? For any GLP-1 telehealth platform, check that clinicians are licensed in your state, medication comes from US-licensed pharmacies, outcome claims are sourced from clinical trials of FDA-approved products rather than self-reported figures, and the platform's current status in LegitScript's public certification database.
Who should pick which
MEDVi may fit if:
- The lowest advertised first-month price is your deciding factor and you've priced the $299/month refills into your budget
- You want an oral form at MEDVi's advertised $249 entry price and a clinician judges it appropriate
- You're comfortable with its published cancellation and refund windows
Pallas is probably the better fit if:
- You want the all-in monthly number to stay low after the intro month — and flat at every dose
- You want brand-name access with no membership fee
- You want nothing charged unless a clinician prescribes, and cancel-anytime flexibility with no notice window
- You want asynchronous care in most states with anytime provider messaging and a self-serve portal
- You'd use a free companion app (iOS and Android) for protein, steps, and dose tracking
Switching between them
Bring your medication name, current dose, and titration history (screenshot or export your records before canceling anywhere). A new provider picks up from your current dose — no restart of titration unless you've been off medication for more than four weeks. Mind the cancellation mechanics: MEDVi's policy requires notice at least 72 hours before your next billing date, so time your switch to avoid paying for an overlapping month. For the clinical side of choosing between molecules, see semaglutide vs tirzepatide.
Bottom line: MEDVi advertises one of the lowest first-month prices in GLP-1 telehealth, with free shipping and oral options — and its own FAQ puts semaglutide injection refills at $299/month after the intro, with a $99/month membership on the brand track and cancellation windows worth reading closely. Pallas is built around the opposite structure: one all-in number that stays low and flat after the intro month, no membership on any tier, nothing charged until a clinician prescribes, cancel-anytime terms, and asynchronous care through a self-serve portal plus a free companion app. Compare the month-four math and the exit terms — that's where these two platforms genuinely differ.
